Fallarino Francesca, Gizzi S, Mosci P, Grohmann U, Puccetti P
Department of Experimental Medicine, Section of Pharmacology, University of Perugia, Via del Giochetto, Perugia 06126, Italy.
Curr Drug Metab. 2007 Apr;8(3):209-16. doi: 10.2174/138920007780362581.
Plasmacytoid dendritic cells (pDCs) represent a specialized cell population that produces large amounts of type I interferons, the so-called natural interferon-producing cells. Recently, murine and human pDCs have been credited with a unique ability to express indoleamine 2,3-dioxygenase (IDO) and to mediate immunosuppression in specific settings. This suggests an important role for IDO-expressing pDCs in controlling the balance of inflammation and tolerance. Here we review recent advances in our understanding of how these cells may be critical at the interface of inflammation and tolerance and discuss the potential for therapeutic IDO modulation as an immunoregulatory maneuver targeting pDC function.
浆细胞样树突状细胞(pDC)是一类特殊的细胞群体,可产生大量I型干扰素,即所谓的天然干扰素产生细胞。最近,小鼠和人类pDC被认为具有独特的能力,能够表达吲哚胺2,3-双加氧酶(IDO)并在特定环境中介导免疫抑制。这表明表达IDO的pDC在控制炎症和耐受平衡方面具有重要作用。在此,我们综述了对这些细胞在炎症与耐受界面可能发挥关键作用的理解的最新进展,并讨论了将IDO调节作为靶向pDC功能的免疫调节策略进行治疗的潜力。